Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform

Cambridge, UK, November 13, 2024 –Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. … Continued The post Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform appeared first on Healx .